Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$2.95 USD
-0.17 (-5.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.12 +0.17 (5.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Anebulo Pharmaceuticals, Inc falls in the month of June.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -11.73 | -6.83 | -30.25 | -0.17 | NA |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | 1.16 | 0.91 | -1.45 | 0.02 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 0.88 | 0.48 | 26.83 | 0.00 | NA |
Net Cash From Operating Activities | -9.68 | -5.44 | -4.87 | -0.15 | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Uses of Funds
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.70 | 0.00 | 20.60 | 3.00 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.20 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.20 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.32 | 0.00 | 1.43 | -0.02 | NA |
Net Cash from Financing Activities | 6.38 | 0.00 | 21.83 | 3.18 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -3.30 | -5.44 | 16.96 | 3.02 | NA |
Cash at Beginning of Period | 14.55 | 19.99 | 3.02 | 0.00 | NA |
Cash at End of Period | 11.25 | 14.55 | 19.99 | 3.02 | NA |
Diluted Net EPS | -0.47 | -0.29 | -2.83 | -0.01 | NA |
Fiscal Year End for Anebulo Pharmaceuticals, Inc falls in the month of June.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -5.20 | -2.48 | -11.73 | -9.24 |
Depreciation/Amortization & Depletion | NA | 0.03 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 0.20 | -0.46 | 1.16 | 1.74 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.43 | 0.21 | 0.88 | 0.66 |
Net Cash From Operating Activities | NA | -4.54 | -2.73 | -9.68 | -6.83 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 0.00 | 6.70 | 6.70 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.06 | 0.00 | -0.32 | -0.25 |
Net Cash from Financing Activities | NA | -0.06 | 0.00 | 6.38 | 6.45 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -4.60 | -2.73 | -3.30 | -0.38 |
Cash at Beginning of Period | NA | 11.25 | 11.25 | 14.55 | 14.55 |
Cash at End of Period | NA | 6.64 | 8.52 | 11.25 | 14.16 |
Diluted Net EPS | NA | -0.11 | -0.10 | -0.10 | -0.11 |